Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur EMERGENT BIOSOLUTIONS INC.
14/01EMERGENT BIOSOLUTIONS INC. : Change in Directors or Principal Officers, Regulation FD Disc..
14/01Emergent Biosolutions Chairman to Retire in April
14/01Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
14/01Emergent BioSolutions Inc. Announces Retirement of Fuad El-Hibri, Founder and Executive..
10/01Emergent BioSolutions to Look for M&A
10/01EMERGENT BIOSOLUTIONS : Announces 2022 Financial Guidance, Provides Preliminary 2021 Resul..
10/01EMERGENT BIOSOLUTIONS INC. : Results of Operations and Financial Condition, Regulation FD ..
10/01Emergent Biosolutions Reports Preliminary 2021 Adjusted Net Income, Revenue In Line Wit..
09/01Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Resu..
09/01Emergent BioSolutions Inc. Provides Earnings Guidance for the Full Year 2022
03/01Emergent BioSolutions to Participate in Investor Conferences
2021Emergent Biosolutions Initiates Phase 1 Study of Universal Influenza Vaccine Candidate
2021Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal In..
2021Emergent BioSolutions Inc Announces Initiation of Phase 1 Study Evaluating Its Universa..
2021Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
2021EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 - Biotechnology
2021EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 Health Care
2021EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400
2021EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600 Health Care
2021EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600
2021Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
2021Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
2021Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Gr..
2021SiTime to Join S&P MidCap 400, Pushing Emergent BioSolutions to S&P SmallCap 600 From N..
2021EMERGENT BIOSOLUTIONS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2021Emergent Biosolutions' Board Approves Repurchases of up to $250 Million Shares; Stock R..
2021Emergent BioSolutions Announces Stock Repurchase Program
2021Emergent BioSolutions Inc. announces an Equity Buyback for $250 million worth of its sh..
2021Emergent BioSolutions Inc. authorizes a Buyback Plan.
2021FDA - Coronavirus (COVID-19) Update
2021Health Care Up After Pfizer Covid Pill Shows Promise -- Health Care Roundup
2021EMERGENT BIOSOLUTIONS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
2021Expedia, Pfizer rise; Peloton, Emergent BioSolutions fall
2021LATE BRIEFING - Unternehmen und Märkte -2-
2021J&J-Auftragsfertiger verliert Regierungsvertrag - Aktie fällt
2021Emergent slumps as U.S. terminates COVID-19 vaccine manufacturing deal
2021COVID : oltre 248,7 mln casi e 5,03 mln morti nel mondo
2021REPORT : US cancels vaccine maker's multimillion dollar deal
2021EMERGENT BIOSOLUTIONS : Q3 Earnings Snapshot
2021Emergent BioSolutions Seeks M&A
2021Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q3 Loss $-0.36, vs. Street Est of $2..
2021GUIDANCE : (EBS) EMERGENT BIOSOLUTIONS Sees Fiscal Year 2021 Revenue Range $1.7B - $1.8B
2021EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021 - Form 8-K
2021EMERGENT BIOSOLUTIONS INC. : Termination of a Material Definitive Agreement (form 8-K)
2021Emergent Biosolutions Inc. and Biomedical Advanced Research and Development Authority E..
2021EMERGENT BIOSOLUTIONS INC. : Results of Operations and Financial Condition, Regulation FD ..
2021Emergent BioSolutions Reports Financial Results For Third Quarter 2021
2021Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
2021INSIDER SELL : Meta Financial Group
2021Johnson & Johnson's COVID-19 Vaccine Doses Remain in Emergent Plant Awaiting FDA Green ..
2021Nearly 50 Million Doses of J&J's COVID-19 Shots Await US FDA Nod
2021Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources
2021Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources
2021EMERGENT BIOSOLUTIONS : Announces Initiation of Pivotal Phase 3 Study Evaluating the Safet..
2021EMERGENT BIOSOLUTIONS : to Release Third Quarter 2021 Financial Results and Conduct a Conf..
2021EMERGENT BIOSOLUTIONS : Emergency BioSolutions Doses First Patient in Phase 3 Trial of Vac..
2021EMERGENT BIOSOLUTIONS : Announces Initiation of Pivotal Phase 3 Study Evaluating the Safet..
2021Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safe..
2021EMERGENT BIOSOLUTIONS : Unit Gets Additional AV7909 Dose Order From BARDA -- Shares Jump
2021EMERGENT BIOSOLUTIONS : Material Definitive Agreement (Form 8-K)
2021EMERGENT BIOSOLUTIONS INC. : Entry into a Material Definitive Agreement (form 8-K)
2021Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19
2021EMERGENT BIOSOLUTIONS : Signs Five-Year, $90 Million Contract With Providence Therapeutics
2021EMERGENT BIOSOLUTIONS : Secures Multi-Year Development and Manufacturing Agreement with Pr..
2021Emergent BioSolutions Inc. Secures Multi-Year Development and Manufacturing Agreement w..
2021EMERGENT BIOSOLUTIONS : FDA - Coronavirus (COVID-19) Update
2021EMERGENT BIOSOLUTIONS : Financial Statements and Exhibits (form 8-K/A)
2021Policías y manifestantes se enfrentan mientras miles marchan en Berlín contra restricci..
2021Ataque en aeropuerto de Kabul mata a decenas de civiles y al menos 13 soldados EEUU
2021EMERGENT BIOSOLUTIONS : Launches Late-Stage Trial of Investigational COVID-19 Plasma-Deriv..
2021Emergent's COVID-19 plasma therapy to be tested in NIH-sponsored study
2021Emergent's COVID-19 therapy to be tested in NIH-sponsored study
2021EMERGENT BIOSOLUTIONS : rsquo; COVID-19 Human Immune Globulin Product Candidate to be Eval..
2021Emergent BioSolutions to Participate in Investor Conferences
2021ASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - ..
1  2  3  4  5  6  7  8  9  10Suiv.
Prochain événement sur EMERGENT BIOSOLUTIONS INC.